<DOC>
	<DOCNO>NCT00144664</DOCNO>
	<brief_summary>This open-label , Phase III study evaluate efficacy , safety PK MRA patient pJIA .</brief_summary>
	<brief_title>Study MRA Polyarticular Juvenile Idiopathic Arthritis ( pJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Inclusion criterion Patients diagnose rheumatoid factor ( RF ) positive negative polyarthritic oligoarthritic JIA accord ILAR standard ( 1997 ) Patients age least 2 year old less 20 . Patients age less 16 year old time onset Exclusion criterion Patients Class IV Steinbrocker functional disorder evaluation within 2 week initiation treatment investigational product Patients treat underlying disease biological agent , infliximab etanercept , within 12 week initiation treatment investigational product</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>